NOVAVAX INC annual report, FY2021

Business context and reporting period

Novavax, Inc.’s 10-K reports the fiscal year ended December 31, 2021; it is not a standalone fourth-quarter report, and the supplied filing text does not provide clear Q4-only financial results. The company develops recombinant vaccines and was focused principally on its COVID-19 vaccine candidate, NVX-CoV2373, alongside influenza, combination-vaccine, RSV and partner-led malaria programs.

By year-end, NVX-CoV2373 had received authorizations in several markets, including EU conditional marketing authorization and WHO emergency use listing. The company submitted an FDA EUA request in January 2022; U.S. authorization had not been received as of the filing.

Financial performance and position

Metric	2021	2020
Revenue	$1.146 billion	$475.6 million
Operating expenses	$2.833 billion	$892.3 million
Operating loss	$1.687 billion	$416.7 million
Net loss	$1.744 billion; $23.44 per share	$418.3 million; $7.27 per share
Cash from operating activities	$322.9 million provided	$42.5 million used

Revenue comprised $948.7 million in grants and $197.6 million in royalties and other revenue. Grant revenue was mainly government and CEPI funding; partner royalties rose with sales in South Korea and Indonesia. Revenue was not predominantly direct product sales by Novavax.
Research and development expense was $2.535 billion, including $2.246 billion for NVX-CoV2373; general and administrative expense was $298.4 million. No clear gross-margin or operating-margin figure is provided.
Cash, cash equivalents and restricted cash totaled $1.528 billion at year-end, compared with $648.7 million at the end of 2020. Cash and cash equivalents were $1.515 billion; marketable securities were zero.
Current assets were $2.155 billion and current liabilities $2.390 billion, a current-liability excess of about $235 million. Current deferred revenue was $1.423 billion; total deferred revenue, including non-current amounts, was about $1.595 billion.
Convertible notes had $325 million principal, a 3.75% coupon and a February 2023 maturity; carrying value was $323.5 million. Total liabilities were $2.928 billion and stockholders’ equity was negative $351.7 million.
Operating cash flow benefited substantially from advance-purchase-agreement payments recorded as deferred revenue; it should not be read as evidence of positive underlying earnings. The company also raised about $565 million net through common-stock sales in 2021.

Material changes versus the prior year

Revenue increased by $670.7 million, while net loss widened by $1.325 billion. Management attributed the larger loss chiefly to the substantial increase in COVID-19 vaccine development and manufacturing activity, partly offset by increased grant revenue and partner royalties.
R&D expense rose by $1.787 billion, primarily from NVX-CoV2373 work. G&A expense increased by $153.1 million, including higher employee-related costs and professional fees.
Operating cash flow improved by $365.5 million, mainly reflecting APA cash receipts and timing of payments, despite the much larger net loss.
Cash and restricted cash increased, supported by APA advances, government funding and equity issuance. Shares outstanding also increased.

Outlook, risks and unusual items

Management expected 2022 revenue to increase significantly, but gave no quantified revenue guidance. It expected R&D expense to decrease significantly, partly because certain manufacturing costs would be capitalized rather than expensed; G&A expense and capital spending were expected to increase, and selling and marketing costs could follow authorizations and approvals.
The company reported projected global NVX-CoV2373 capacity exceeding two billion annualized doses at full capacity. This is a projection, not evidence of actual production or deliveries. Manufacturing scale-up, quality testing, regulatory acceptance and partner execution remain material uncertainties.
The U.S. government directed Novavax to align analytical methods with FDA requirements before further U.S. manufacturing and said it would not fund additional U.S. manufacturing until alignment. The deadline was extended to April 2022. OWS authorized funding remained $1.75 billion, despite a revised contract ceiling of approximately $1.8 billion.
About $8 billion of transaction price was allocated to unsatisfied or partially unsatisfied performance obligations at year-end, excluding sales-based royalties. Fulfillment depends on development work, manufacturing, deliveries and authorizations; it is not equivalent to recognized revenue or assured cash receipts. APA advances may be refundable in specified circumstances, including missed regulatory or supply conditions.
Management identified ongoing losses, continued funding needs, intense competition, uncertain vaccine demand and profitability, dependence on third-party manufacturers, regulatory and variant risks, and potential repayment of advances as key risks. The $325 million notes mature in 2023 and require refinancing or repayment planning.
Unusual accounting and expense items included $144.4 million of right-of-use assets expensed for manufacturing arrangements without alternative future use. The auditor reported an unqualified opinion on the financial statements and internal controls, while identifying government-contract revenue estimates and embedded manufacturing leases as critical audit matters.
A securities class action and related derivative suits alleged misleading statements about manufacturing capability and regulatory and commercial prospects; the company said the financial impact was not estimable. A separate equity-award derivative action was stayed pending a fee motion.

Most important facts for investors to verify

Whether FDA authorization was obtained and whether other regulatory submissions, including pediatric applications, advanced on the expected timelines.
Actual production, regulatory compliance, deliveries and commercial sales versus projected capacity and APA commitments, including COVAX and partner supply.
Cash conversion and the terms, timing and potential refundability of the substantial deferred revenue and customer advances.
2022 revenue, expense and capital-spending trends against management’s unquantified outlook, including the effect of capitalizing manufacturing costs.
Liquidity and financing plans for the 2023 convertible-note maturity, lease obligations and purchase commitments, as well as potential dilution from additional share issuance.
Developments in the securities and derivative litigation and any resulting financial, operational or reputational exposure.